



Bayesian Hierarchical Models

Gavin Shaddick,
Millie Green, Matthew Thomas
University of Bath

6th - 9th December 2016

APPLICATIONS OF BAYESIAN HIERARCHICAL MODELS

OUTLINE

Spatial epidemiology

Disease mapping

Statistical methods for smoothing risks

Spatial epidemiology

WHAT IS SPATIAL EPIDEMIOLOGY?

- ▶ Epidemiology is the study of the distribution of diseases in human populations.
- ▶ Disease risk depends on the classic epidemiological triad of person (genetics/behaviour), place and time.
- ▶ Spatial epidemiology focuses on the second of these.
- ▶ Place is a surrogate for exposures present at that location
 - ▶ environmental exposures in water/air/soil
 - ▶ lifestyle characteristics of those living in particular areas.

GROWING INTEREST IN SPATIAL EPIDEMIOLOGY

- ▶ Public interest in effects of environmental hazards/pollution.
- ▶ Epidemiological interest in differences in disease rates across different areas.
- ▶ Data availability: collection of health data at different geographical scales.
- ▶ Increase in computing power and methods
 - ▶ Geographical Informations Systems (GIS).
- ▶ Development of statistical/epidemiological methods for investigating disease 'clusters'.

THE NEED FOR SPATIAL METHODS

- ▶ Many epidemiological studies are spatial
 - ▶ many are spatio-temporal!
- ▶ When do we need to 'worry'?
 - ▶ acknowledge the spatial component
 - ▶ are we explicitly interested in the spatial pattern of disease incidence?
 - ▶ disease mapping
 - ▶ cluster detection.
 - ▶ is the clustering a nuisance quantity that we wish to acknowledge, but are not explicitly interested in?
 - ▶ spatial regression.

TYPES OF SPATIAL DATA

- ▶ **Point data**
 - ▶ 'exact' residential locations exist for cases and controls.
- ▶ **Count data**
 - ▶ aggregation
 - ▶ typically over administrative units
 - ▶ ecological, in that they are collected across groups
 - ▶ in spatial studies the groups are geographical areas.

Disease mapping

OVERVIEW OF DISEASE MAPPING

- ▶ The estimation and presentation of summary measures of health outcomes.
- ▶ The aims of disease mapping include
 - ▶ simple description
 - ▶ hypothesis generation
 - ▶ allocation of health care resources, assessment of inequalities
 - ▶ estimation of background variability in underlying risk in order to place epidemiological studies in context.
- ▶ Unfortunately there are well-documented difficulties with the mapping of raw estimates since, for small areas and rare diseases in particular, these estimates will be dominated by sampling variability.

EXAMPLE: LIP CANCER IN SCOTLAND

- ▶ Incidence rates of lip cancer in males in 56 counties of Scotland, registered in 1975–1980.
- ▶ Data
 - ▶ observed and ‘expected’ number of cases (based on the county age populations)
 - ▶ this allows the calculation of the standardised morbidity ratio
 - ▶ ratio of the observed to the expected cases.
 - ▶ a covariate measuring the proportion of the population engaged in agriculture, fishing, or forestry (AFF)
 - ▶ the projections of the longitude and latitude of the area centroid, and the ‘position’ of each county expressed as a list of adjacent counties.

EXAMPLE: LIP CANCER IN SCOTLAND

| County No. i | Obs Cases Y_i | Exp Cases E_i | Prop AFF | SMR | Project N (km) | Project E (km) | Adjacent Counties |
|-------------------|--------------------|--------------------|-------------|------|-------------------|-------------------|-------------------------|
| 1 | 9 | 1.4 | 0.16 | 6.43 | 834.7 | 162.2 | 5,9,19 |
| 2 | 39 | 8.7 | 0.16 | 4.48 | 852.4 | 385.8 | 7,10 |
| 3 | 11 | 3.0 | 0.10 | 3.67 | 946.1 | 294.0 | 12 |
| 4 | 9 | 2.5 | 0.24 | 3.60 | 650.5 | 377.9 | 18,20,28 |
| 5 | 15 | 4.3 | 0.10 | 3.49 | 870.9 | 220.7 | 1,12,19 |
| 6 | 8 | 2.4 | 0.24 | 3.33 | 1015.2 | 340.2 | Island |
| 7 | 26 | 8.1 | 0.10 | 3.21 | 842.0 | 325.0 | 2,10,13,16,17 |
| 8 | 7 | 2.3 | 0.07 | 3.04 | 1168.9 | 442.2 | Island |
| 9 | 6 | 2.0 | 0.07 | 3.00 | 781.4 | 194.5 | 1,17,19,23,29 |
| ... | | | | | | | |
| 47 | 2 | 5.6 | 0.01 | 0.36 | 640.8 | 277.0 | 24,31,46,48,49,53 |
| 48 | 3 | 9.3 | 0.01 | 0.32 | 654.7 | 282.0 | 24,44,47,49 |
| 49 | 28 | 88.7 | 0.00 | 0.32 | 666.7 | 267.8 | 38,41,44,47,48,52,53,54 |
| 50 | 6 | 19.6 | 0.01 | 0.31 | 736.5 | 342.2 | 21,29 |
| 51 | 1 | 3.4 | 0.01 | 0.29 | 678.9 | 274.9 | 34,38,42,54 |
| 52 | 1 | 3.6 | 0.00 | 0.28 | 683.7 | 257.8 | 34,40,49,54 |
| 53 | 1 | 5.7 | 0.01 | 0.18 | 646.6 | 265.6 | 41,46,47,49 |
| 54 | 1 | 7.0 | 0.01 | 0.14 | 682.3 | 267.9 | 34,38,49,51,52 |
| 55 | 0 | 4.2 | 0.16 | 0.00 | 640.1 | 321.5 | 18,24,30,33,45,56 |
| 56 | 0 | 1.8 | 0.10 | 0.00 | 589.9 | 322.2 | 18,20,24,27,55 |

EXAMPLE: LIP CANCER IN SCOTLAND




Figure: SMRs for male lip cancer in 56 counties of Scotland.

EXAMPLE: LUNG AND BRAIN CANCER IN NORTH-WEST ENGLAND

- ▶ Two tumors
 - ▶ one non-rare (lung)
 - ▶ and one rare (brain).
- ▶ Study period is 1981–1991.
- ▶ Analysis performed at ward level (144 wards)
 - ▶ incidence data by postcode.
- ▶ Brain cancer
 - ▶ the median number of cases per ward over the 11 year period is 6
 - ▶ range of 0 to 17.
- ▶ Lung cancer
 - ▶ the median number is 20
 - ▶ range 0–60.
- ▶ ‘Expected counts’ were based on ward-level populations from the 1991 census, by 5-year age bands and sex.

EXAMPLE: LUNG AND BRAIN CANCER IN NORTH-WEST ENGLAND




Figure: SIRs for (a) lung cancer, and (b) brain cancer in the North-West of England.

NON-STATISTICAL ISSUES

- ▶ There is a trade-off when a geographical scale is chosen
 - ▶ larger geographical areas provide more stable rates
 - ▶ relative risk summaries may be distorted due to the large aggregation of individuals.
- ▶ If the relative risk shows marked variation within a particular area this information will be lost
 - ▶ high relative risks will be diluted under aggregation.
- ▶ The size of the areas chosen also determines the sort of questions that can be posed
 - ▶ larger areas often mean greater contrasts in relative risks and exposures
 - ▶ localized effects can only be detected with data at a smaller level of aggregation.

STATISTICAL ISSUES

- ▶ Unfortunately there are well-documented difficulties with the mapping of raw estimates since, for small areas and rare diseases in particular, these estimates will be dominated by sampling variability.
- ▶ For the model

$$Y_i \sim \text{Poisson}(E_i\theta_i)$$

statistically, the best estimate of the rate $\hat{\theta}_i$ will be

$$\hat{\theta}_i = \text{SMR}_i = \frac{Y_i}{E_i}$$

with variance


$$\text{var}(\hat{\theta}_i) = \frac{\theta_i}{E_i}$$

so that areas with small E_i have high associated variance.

EXAMPLE: SCOTTISH LIP CANCER

- ▶ The variance of the estimate is $\text{var}(\text{SMR}_i) = \text{SMR}_i/E_i$.
- ▶ This will be large if E_i is small.
- ▶ For the Scottish data the expected numbers are highly variable, with range 1.1–88.7.
- ▶ This variability suggests that there is a good chance that the extreme SMRs are based on small expected numbers
 - ▶ many of the large, sparsely populated, rural areas in the north have high SMRs.

SMR estimates



SMOOTHING MODELS

- ▶ The above considerations led to methods being developed to *smooth* the SMRs.
- ▶ Use hierarchical/random effects models that use the data from all of the areas to provide more reliable estimates in each of the constituent areas.

Statistical methods for smoothing risks

SPATIAL MODELS

- ▶ In general we might expect relative risks in areas that are 'close' to be more similar than in areas that are not 'close'.
- ▶ We would like to exploit this information in order to provide more reliable relative risk estimates in each area.
- ▶ This is analogous to the use of a covariate x , in that areas with similar x values are likely to have similar relative risks.
- ▶ Unfortunately the modelling of spatial dependence is much more difficult since spatial location is acting as a surrogate for unobserved covariates.
- ▶ We need to choose an appropriate spatial model, but do not directly observe the covariates whose effect we are trying to mimic.

- ▶ Consider the model

$$Y_i | \beta, \gamma, \mathbf{U}_i, \mathbf{V}_i \sim \text{Poisson}(\mathbf{E}_i \mu_i e^{\mathbf{U}_i + \mathbf{V}_i})$$

$$\log \mu_i = g(\mathbf{S}_i, \gamma) + \mathbf{f}(\mathbf{x}_i, \beta),$$

- ▶ $\mathbf{S}_i = (S_{i1}, S_{i2})$ denotes spatial location, the centroid of area i ,
- ▶ $\mathbf{f}(\mathbf{x}_i, \beta)$ is a regression model,
- ▶ $g(\mathbf{S}_i, \gamma)$ is an expression that we may include to capture large-scale spatial trend, e.g. long-term spatial trend

$$f(\mathbf{S}_i) = \gamma_1 S_{i1} + \gamma_2 S_{i2},$$

- ▶ The random effects $V_i \sim_{iid} N(0, \sigma_v^2)$ represent non-spatial overdispersion,
- ▶ U_i are random effects with spatial structure.

- ▶ One approach is to specify the distribution of the random effect for a particular area, U_i , as if we knew the values of the spatial random effects, U_j , in 'neighbouring areas'
- ▶ We therefore need to specify a rule for determining the 'neighbours' of each area.
- ▶ Commonly areas i and j are taken to be neighbours if they share a *common boundary*.

- ▶ Various other neighbourhood/weighting schemes are possible.
- ▶ The neighbourhood structure could depend on the distance between area centroids.
- ▶ Determine the distance within which regions are considered neighbours.




Figure: Close-up of a region of Birmingham.

The ICAR model

- ▶ A common model is to assign the spatial random effects an intrinsic conditional autoregressive (ICAR) prior.
- ▶ Under this specification it is assumed that

$$U_i | U_j, j \in \partial i \sim N \left(\bar{U}_i, \frac{\omega_u^2}{m_i} \right),$$

where ∂i is the set of neighbours of area i , m_i is the number of neighbours, and \bar{U}_i is the mean of the spatial random effects of these neighbours.

- ▶ The parameter ω_u^2 is a conditional variance and its magnitude determines the amount of spatial variation.
- ▶ The variance parameters σ_v^2 and ω_u^2 are on different scales, σ_v is on the log odds scale while ω_u is on the log odds scale, *conditional* on $U_j, j \in \partial i$; hence they are not comparable.

- ▶ Notice that if ω_u^2 is 'small' then although the residual is strongly dependent on the neighboring value the overall contribution to the residual relative risk is small.
- ▶ This is a little counterintuitive but stems from spatial models having two aspects, strength of dependence and total amount of spatial dependence, and in the ICAR model there is only a single parameter which controls both aspects.

Recall the model

$$Y_i | \beta, \gamma, U_i, V_i \sim_{ind} \text{Poisson}(E_i \mu_i e^{U_i + V_i})$$

with

$$\log \mu_i = g(\mathbf{S}_i, \gamma) + f(\mathbf{x}_i, \beta), \quad (1)$$

where

- ▶ $\mathbf{S}_i = (S_{i1}, S_{i2})$ denotes spatial location, the centroid of area i ,
- ▶ $f(\mathbf{x}_i, \beta)$ is a regression model,
- ▶ $g(\mathbf{S}_i, \gamma)$ is an expression that we may include to capture large-scale spatial trend – the form

$$f(\mathbf{S}_i) = \gamma_1 S_{i1} + \gamma_2 S_{i2},$$

is a simple way of accommodating long-term spatial trend.

- ▶ The random effects $V_i \sim_{iid} N(0, \sigma_v^2)$ represent non-spatial overdispersion,
- ▶ U_i are random effects with spatial structure which we now consider ‘jointly’ rather than considering neighbours.

A Joint Model

- ▶ Assume that $\mathbf{U} = (U_1, \dots, U_n)$ arise from a zero mean multivariate normal distribution with variances $\text{var}(U_i) = \sigma_u^2$ and correlations $\text{corr}(U_i, U_j) = \exp(-\phi d_{ij}) = \rho^{d_{ij}}$ where d_{ij} is the distance between the centroids of areas i and j , and $\rho > 0$ is a parameter that determines the extent of the correlation.
- ▶ This model is *isotropic* since it assumes that the correlation is the same in all spatial directions. We refer to this as the *joint* model, since we have specified the joint distribution for \mathbf{U} .
- ▶ More generally the correlations can be modeled as $\text{corr}(U_i, U_j) = \exp(-(\phi d_{ij})^\kappa)$.

BAYESIAN ANALYSIS

- ▶ Inference for models with a spatial component is often not straightforward using likelihood based approaches, and so Bayesian methods are commonly used.
- ▶ Unfortunately, most Bayesian models are not conducive to analytical analysis, and so are not available in standard software packages.
- ▶ Markov chain Monte Carlo (MCMC)
 - ▶ Win/OpenBUGS is a package that allows very general Bayesian modeling
 - ▶ GeoBUGS module contains a number of useful spatial models, and mapping facilities
 - ▶ Packages in R, for example CARBayes.
- ▶ Approximate Bayesian inference, for fast computation on big datasets
 - ▶ R-INLA.

EXAMPLE: LIP CANCER IN SCOTLAND



Figure: (a) Unsmoothed SMRs and (b) Smoothed SMRs for lung cancer in the North-West of England.

EXAMPLE: LUNG AND BRAIN CANCER IN NORTH-WEST ENGLAND




Figure: (a) Unsmoothed SIRs and (b) Smoothed SIRs for lung cancer in the North-West of England.

EXAMPLE: LUNG AND BRAIN CANCER IN NORTH-WEST ENGLAND




Figure: (a) Unsmoothed SIRs and (b) Smoothed SIRs for brain cancer in the North-West of England.

SUMMARY OF SMOOTHING IN DISEASE MAPPING

- ▶ The aim is to reduce the instability inherent in SMRs based on small expected numbers.
- ▶ This is achieved by fitting a random effects model which assumes that area-level deviations from the regression model arise from a probability distribution.
- ▶ Comparing SMRs with smoothed estimates is important
 - ▶ if there are big changes, are they appropriate?
 - ▶ were the expected numbers small?
 - ▶ did the regression model fit this area well?